BCL10 expression is unrelated to clinico-pathological parameters or prognoses for oral squamous cell carcinomas

Biotechnic and Histochemistry

Volumn 87, Issue 6, 2012, Pages 423-427

  Moar Antelo, A R ^a   Perez Sayans M ^a   Suarez Penaranda J M ^b   Gayoso Diz, P ^c   Barros Angueira, F ^b   Gandara Rey J M ^a   Garcia Garcia A ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c Santiago University Clinical Hospital   (Spain)

Author keywords

B cell lymphoma; BCL 10; Oral squamous cell carcinoma

Indexed keywords

BCL10 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84863891338     PISSN: 10520295     EISSN: 14737760     Source Type: Journal    
DOI: 10.3109/10520295.2012.695025     Document Type: Article

References (9)

1. American Joint Committee on Cancer (2010) Chapter 3. Lip and oral cavity. In: Edge SB, Fritz AG, Byrd DR, Greene FL, Trotti A III, Compton CC, Eds., Cancer Staging Manual, 7 th ed., Springer, Chicago, IL. pp. 1-4.
2. Chang HH, Kuo MY, Cheng SJ, Chiang CP (2009) Expression of BCL10 is signifi cantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. Oral Oncol. 45: 589-593.
3. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profi ling of tumor specimens. Nat. Med. 4: 844-847. (Pubitemid 28331029)
4. La Rosa S, Franzi F, Marchet S, Finzi G, Clerici M, Vigetti D, Chiaravalli AM, Sessa F, Capella C (2009) The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specifi c marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. Virchows Arch. 454: 133-142.
5. Lambers AR, Gumbs C, Ali S, Marks JR, Iglehart JD, Berchuck A, Futreal PA (1999) Bcl10 is not a target for frequent mutation in human carcinomas. Br. J. Cancer 80: 1575-1576. (Pubitemid 29308638)
6. Lee SH, Shin M S, Kim HS, Park WS, Kim SY, Lee HK, Park JY, Oh RR, Jang JJ, Park KM, Han JY, Kang CS, Lee JY, Yoo NJ (1999) Point mutations and deletions of the Bcl10 gene in solid tumors and malignant lymphomas. Cancer Res. 59: 5674-5677.
7. Rehman AO, Wang CY (2009) CXCL12/SDF-1 alpha activates NF-kappa B and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex. Int. J. Oral Sci. 1: 105-118.
8. Willis TG, Jadayel DM, Du M Q, Peng H, Perry AR, Abdul-Rauf M, Price H, Karran L, Majekodunmi O, Wlodarska I, Pan L, Crook T, Hamoudi R, Isaacson P G, Dyer MJ (1999) Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96: 35-45. (Pubitemid 29044151)
9. Zhang Q, Siebert R, Yan M, Hinzmann B, Cui X, Xue L, Rakestraw KM, Naeve CW, Beckmann G, Weisenburger DD, Sanger WG, Nowotny H, Vesely M, Callet-Bauchu E, Salles G, Dixit VM, Rosenthal A, Schlegelberger B, Morris SW (1999) Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32) Nat. Genet. 22: 63-68. (Pubitemid 29214806)